This site is intended for U.S. residents only. For Novartis Worldwide, Click here

Mailing List


	Sign up and receive information about Novartis clinical trials in your health-related areas of interest. For U.S. residents only.

Study Description

Screening

Study Centers

Contact/Consent

Rheumatoid Arthritis

In this chronic disease various joints in the body are inflamed, leading to swelling, pain, stiffness, and possibly loss of function. Continuous inflammation gradually erodes the joint cartilage, narrows the joint space and eventually damages bone. The inflammatory process not only affects the joints but can also harm organs in other parts of the body.

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

How to use this system:

The purpose of this system is to help connect interested study participants with clinical research centers. The following is a brief outline explaining the main steps involved in using this system. Please note that every step in this process is optional.

1. Select a clinical trial that you feel best suits your (or the      participant's) health condition.
2. Answer the screening questions to see if you (or the      participant) meet the preliminary qualifications for the study.      The answers to these questions are not retained by this      system.
3. Select a study center to contact for additional information      about the clinical trial.
4. Set up an account and agree to the terms of use for this      system.
5. Submit your information to the study center you selected.
6. The study center may contact you and may ask more      questions about your (or the participant's) eligibility for the      study. The study center may invite you (and the participant if      applicable) to travel to the study center for additional screening      tests. Novartis cannot guarantee that you will be contacted by      the study center.
7. If you are eligible to participate in the study, then you will be      required to sign an informed consent before enrolling in the      study. An informed consent is provided to you to help you      understand the clinical trial, the nature of the medical treatment      (if any), procedures and known risks involved, before you agree      to participate in the study.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Rheumatoid Arthritis Study CAIN457A2101

The purpose of this clinical research study is to evaluate which dose level of the investigational drug is most effective in participants with rheumatoid arthritis. Participants will be given either study medicine or a placebo in a random fashion (like flipping a coin). The investigational drug being tested in this study is currently not on the market (available for you to buy) in any country. This is a phase 1 study which means that this is the first time that the study drug will be studied in humans.
Trial phase: Phase 1
Participation Duration: Participants will be asked to come to the study center 16 times over a 16 week period. Each visit will require a stay of at least 48 hours, one day before dosing and one day after dosing.
Protocol Number: CAIN457A2101

	Site Map \| Contact Us \| Clinical Trial Search \| Mailing List \| Clinical Trial FAQs
	Participation FAQs \| Clinical Trials Glossary \| About Informed Consent
	Novartis Medical and Clinical Research

Clinical Trial Search

Rheumatoid Arthritis